Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study

BACKGROUND: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of mater...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Clowse, Megan EB, Förger, Frauke, Hwang, Caroline, Thorp, John, Dolhain, Radboud JEM, van Tubergen, Astrid, Shaughnessy, Laura, Simpson, Jeff, Teil, Marie, Toublanc, Nathalie, Wang, Maggie, Hale, Thomas W
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705850/
https://ncbi.nlm.nih.gov/pubmed/28814432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211384
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados